Following a recent announcement by the Federal Government, major changes to the funding of medications under the opioid treatment program (which include methadone and buprenorphine pharmacotherapies for the treatment of opioid use disorder) will commence on 1 July 2023.
In this special webinar Q&A session, OTAC will provide an update on this announcement and what it may mean for health professionals who provide opioid treatment pharmacotherapies in various settings within New South Wales. Leading the discussion will be Prof Paul Haber, Clinical Director of Drug Health Services SLHD & Head of the Specialty of Addiction Medicine at the University of Sydney.
Have a question? You can submit your questions for the webinar within your registration or use the chat function within Zoom during the session.
This webinar will be recorded and be made available on the OTAC website alongside other relevant resources related to the topic.
The OTAC is managed by the University of Sydney Specialty of Addiction Medicine with funding from the NSW Ministry of Health.